Tracers / [125I]I-BO530

[125I]I-BO530

Radionuclide: I-125 t½ 85666 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer

What it is

Compound class: GRPR/PSMA bispecific heterodimer (urea-based PSMA-617 linked to bombesin-based RM26 antagonist)
Target / mechanism: Dual targeting of gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA) PMID 31340483
Clinical application: Theranostics application in prostate cancer PMID 31340483
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	69% ± 1%	at least 95%	BO530	31340483 2019 Pharmaceutics The heterodimers were radiolabeled with I-125 using Pierce Iodination Reagent (IodoGen) (Thermo Fisher Scientific, Waltham, MA, USA). — radiochemical yields 69% ± 1%, 73% ± 4%, 73% ± 3% for BO530 (Figure 2), BO535, and BO536, respectively

Need this precursor?We can point you to suppliers for [125I]I-BO530, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 31340483. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.